CULLINAN THERAPEUTICS, INC. Income (Loss) Attributable to Noncontrolling Interest, before Tax
CULLINAN THERAPEUTICS, INC. (CGEM) reported Income (Loss) Attributable to Noncontrolling Interest, before Tax of -$800.00 thousand for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossAttributableToNoncontrollingInterest · last filed 2022-05-16
- CULLINAN THERAPEUTICS, INC. income (loss) attributable to noncontrolling interest, before tax for the quarter ending 2022-03-31 was -$800.00K, a 153.33% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. income (loss) attributable to noncontrolling interest, before tax for the quarter ending 2021-12-31 was $2.10M, a 85.62% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. income (loss) attributable to noncontrolling interest, before tax for the quarter ending 2021-09-30 was -$900.00K.
- CULLINAN THERAPEUTICS, INC. income (loss) attributable to noncontrolling interest, before tax for the quarter ending 2021-06-30 was -$800.00K, a 115.09% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. income (loss) attributable to noncontrolling interest, before tax for fiscal 2021 was $1.90M, a 75.32% decline from fiscal 2020.
- CULLINAN THERAPEUTICS, INC. income (loss) attributable to noncontrolling interest, before tax for fiscal 2020 was $7.70M.
| Period end | Income (Loss) Attributable to Noncontrolling Interest, before Tax 3 month | Income (Loss) Attributable to Noncontrolling Interest, before Tax 3 month as first filed | Income (Loss) Attributable to Noncontrolling Interest, before Tax 6 month | Income (Loss) Attributable to Noncontrolling Interest, before Tax 9 month | Income (Loss) Attributable to Noncontrolling Interest, before Tax 12 month |
|---|---|---|---|---|---|
| 2022-03-31 | -$800.00K 10-Q · filed 2022-05-16 | $1.30M derived: sum of 2 quarters · filed 2022-05-16 | $400.00K derived: sum of 3 quarters · filed 2022-05-16 | -$400.00K derived: sum of 4 quarters · filed 2022-05-16 | |
| 2021-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $1.20M derived: sum of 2 quarters · filed 2022-03-17 | $400.00K derived: sum of 3 quarters · filed 2022-03-17 | $1.90M 10-K · filed 2022-03-17 | |
| 2021-09-30 | -$900.00K 10-Q · filed 2021-11-09 | -$1.70M derived: sum of 2 quarters · filed 2021-11-09 | -$200.00K 10-Q · filed 2021-11-09 | $14.40M derived: sum of 4 quarters · filed 2022-05-16 | |
| 2021-06-30 | -$800.00K 10-Q · filed 2021-08-10 | $700.00K 10-Q · filed 2021-08-10 | $15.30M derived: sum of 3 quarters · filed 2022-05-16 | $13.80M derived: sum of 4 quarters · filed 2022-05-16 | |
| 2021-03-31 | $1.50M 10-Q · filed 2022-05-16 | -$1.50M 10-Q · filed 2021-05-14 | $16.10M derived: sum of 2 quarters · filed 2022-05-16 | $14.60M derived: sum of 3 quarters · filed 2022-05-16 | $19.90M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $14.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $13.10M derived: sum of 2 quarters · filed 2022-03-17 | $18.40M derived: sum of 3 quarters · filed 2022-03-17 | $7.70M 10-K · filed 2022-03-17 | |
| 2020-09-30 | -$1.50M 10-Q · filed 2021-11-09 | $3.80M derived: sum of 2 quarters · filed 2021-11-09 | -$6.90M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $5.30M 10-Q · filed 2021-08-10 | -$5.40M 10-Q · filed 2021-08-10 | |||
| 2020-03-31 | $200.00K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |